FDA
-
-
-
-
-
-
-
Seelos Therapeutics (SEEL) Reports Top Line Results from SLS-002 Phase II Study in Adults
-
-
-
-
-
-
-
Seelos Therapeutics to Sponsor and Participate in Wonderland, the World's Leading Psychedelic Event
-
-
-
-
-
-
-
Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase the Remaining Royalties Payable to Phoenixus AG for SLS-002 (Intranasal Racemic Ketamine Program), All Future Success and Com
-
-
-
-
-
-
-
Seelos Therapeutics (SEEL) Announces FDA Acceptance of IND and Grant of Fast Track Designation for SLS-005 (IV Trehalose) for the Treatment of Spinocerebellar Ataxia
-
-
-
-
-
-
-
Seelos Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis (ALS)
-
-
-
-
-
-
-
Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program)
-
-
-
-
-
-
-
Seelos Therapeutics Announces the Selection of SLS-005 (Trehalose) for the HEALEY ALS Platform Trial for Amyotrophic Lateral Sclerosis Led by the Harvard Medical School
-
322,198 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

